Document is current
Any future updates will be listed below
-
Authors
Singh, Inder Paul
Reiss, George R.
Flowers, Brian E.
Katz, L. Jay
Usner, Dale W. https://orcid.org/0000-0002-2799-0652
Applegate, David
Kothe, Angela C. https://orcid.org/0009-0000-7971-5292
Navratil, Tomas https://orcid.org/0009-0007-3577-3096
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03868124 at ClinicalTrials.govDocuments that mention this clinical trial
Administration of the Travoprost Intracameral Implant in an Office-Based Surgery Setting
https://doi.org/10.1007/s40123-025-01254-4
Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses from Two Phase III Trials
https://doi.org/10.1007/s40265-024-02074-9
- License Information
-
More Information
Article History
Received: 2 August 2025
Accepted: 19 September 2025
First Online: 4 October 2025
Declarations
:
: Inder Paul Singh has received consulting fees from Allergan/AbbVie, Alcon, Bausch + Lomb, Glaukos, iStar Medical, New World Medical, Nova Eye, and Sight Sciences; and lecture fees from Allergan/AbbVie, Alcon, Bausch + Lomb, Glaukos, iStar Medical, New World Medical, Nova Eye, Sight Sciences, Thea, and Viatris. George R. Reiss has received consulting fees from Alcon, Allergan/AbbVie, Elios, Glaukos, iStar Medical, New World Medical, Sanoculis, Spyglass, Radius XR, and WL Gore & Associates. Brian E. Flowers has received consulting fees from Alcon, Glaukos, iSTAR Medical, New World Medical, Nicox, Sanoculis, and Sight Sciences. L. Jay Katz, Angela C. Kothe, and Tomas Navratil are employees of Glaukos Corporation and may hold stock and/or stock options. Dale W. Usner was an employee of Glaukos Corporation at the time this analysis was conducted and held stock and/or stock options, and continues to serve as a consultant to Glaukos Corporation. David Applegate was an employee of Glaukos Corporation at the time of this analysis and continues to serve as a consultant to Glaukos Corporation.
: Human subjects were included in this trial. The trial was registered at ClinicalTrials.gov (NCT03868124) and was performed in accordance with the tenets of the Declaration of Helsinki of 1964 and its later amendments, and with approval of the relevant Institutional Review Board (WCG Institutional Review Board, Puyallup, WA, USA [reference number 20181794]. All subjects provided informed consent to participate in the study.
